OPRM1 and inflammatory bowel disease: MOR agonists have been demonstrated to alleviate colitis in preclinical models of IBD by dampening inflammatory cytokine production, including TNF-α [10], while chronic opioid use in IBD patients correlates with adverse clinical outcomes [11].